IL257065B - Antibodies to tfr for use in the treatment of proliferative and inflammatory diseases - Google Patents

Antibodies to tfr for use in the treatment of proliferative and inflammatory diseases

Info

Publication number
IL257065B
IL257065B IL257065A IL25706518A IL257065B IL 257065 B IL257065 B IL 257065B IL 257065 A IL257065 A IL 257065A IL 25706518 A IL25706518 A IL 25706518A IL 257065 B IL257065 B IL 257065B
Authority
IL
Israel
Prior art keywords
antibody
seq
tfr
protein
antibodies
Prior art date
Application number
IL257065A
Other languages
English (en)
Hebrew (he)
Other versions
IL257065A (en
Inventor
Launay Pierre
Belanger Coralie
SOUCHET Herve
Original Assignee
Inatherys
Launay Pierre
Belanger Coralie
SOUCHET Herve
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inatherys, Launay Pierre, Belanger Coralie, SOUCHET Herve filed Critical Inatherys
Publication of IL257065A publication Critical patent/IL257065A/en
Publication of IL257065B publication Critical patent/IL257065B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
IL257065A 2015-07-22 2016-07-21 Antibodies to tfr for use in the treatment of proliferative and inflammatory diseases IL257065B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15306192 2015-07-22
PCT/EP2016/067465 WO2017013230A1 (en) 2015-07-22 2016-07-21 ANTI-TfR ANTIBODIES AND THEIR USE IN TREATING PROLIFERATIVE AND INFLAMMATORY DISORDERS

Publications (2)

Publication Number Publication Date
IL257065A IL257065A (en) 2018-03-29
IL257065B true IL257065B (en) 2022-07-01

Family

ID=53776520

Family Applications (1)

Application Number Title Priority Date Filing Date
IL257065A IL257065B (en) 2015-07-22 2016-07-21 Antibodies to tfr for use in the treatment of proliferative and inflammatory diseases

Country Status (22)

Country Link
US (2) US11230605B2 (OSRAM)
EP (1) EP3325509B1 (OSRAM)
JP (1) JP6858185B2 (OSRAM)
KR (1) KR102690998B1 (OSRAM)
CN (1) CN107849136B (OSRAM)
AU (1) AU2016296321B2 (OSRAM)
CA (1) CA2992509C (OSRAM)
CY (1) CY1123941T1 (OSRAM)
DK (1) DK3325509T3 (OSRAM)
ES (1) ES2860988T3 (OSRAM)
HR (1) HRP20210393T1 (OSRAM)
HU (1) HUE053296T2 (OSRAM)
IL (1) IL257065B (OSRAM)
LT (1) LT3325509T (OSRAM)
MX (1) MX2018000569A (OSRAM)
PL (1) PL3325509T3 (OSRAM)
PT (1) PT3325509T (OSRAM)
RS (1) RS61586B1 (OSRAM)
RU (1) RU2737637C2 (OSRAM)
SI (1) SI3325509T1 (OSRAM)
SM (1) SMT202100134T1 (OSRAM)
WO (1) WO2017013230A1 (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI787796B (zh) 2015-05-04 2022-12-21 美商Ｃｙｔｏｍｘ生物製藥公司 抗ｃｄ７１抗體類、可活化之抗ｃｄ７１抗體類及使用彼等之方法
FR3062213B1 (fr) 2017-01-20 2021-02-26 Endodiag Utilisation du recepteur cd71 dans la detection et le traitement de l’endometriose
EP3552631A1 (en) * 2018-04-10 2019-10-16 Inatherys Antibody-drug conjugates and their uses for the treatment of cancer
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
JP2021533200A (ja) 2018-08-02 2021-12-02 ダイン セラピューティクス, インコーポレーテッドDyne Therapeutics, Inc. 顔面・肩甲・上腕筋ジストロフィーを処置するための筋標的化複合体およびそれらの使用
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US20210308273A1 (en) 2018-08-02 2021-10-07 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
EP4069745A4 (en) * 2019-11-06 2024-05-29 The Regents Of The University Of California COMPOSITIONS AND METHODS FOR TRANSFERRIN RECEPTOR 1 TARGETING
MX2022009418A (es) * 2020-01-31 2022-08-25 Dyne Therapeutics Inc Anticuerpo del receptor anti-transferrina (tfr) y usos del mismo.
US11638761B2 (en) * 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11648318B2 (en) 2021-07-09 2023-05-16 Dyne Therapeutics, Inc. Anti-transferrin receptor (TFR) antibody and uses thereof
EP4366784A1 (en) 2021-07-09 2024-05-15 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating dystrophinopathies
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11969475B2 (en) * 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11827702B2 (en) 2021-09-01 2023-11-28 Biogen Ma Inc. Anti-transferrin receptor antibodies and uses thereof
TW202330601A (zh) * 2021-09-13 2023-08-01 德州大學系統董事會 ＴｆＲ抗原結合蛋白及其用途
KR20250004770A (ko) * 2022-04-15 2025-01-08 다인 세라퓨틱스, 인크. 근긴장성 이영양증을 치료하기 위한 근육 표적화 복합체 및 제제
CN120282983A (zh) * 2022-12-02 2025-07-08 百奥赛图(北京)医药科技股份有限公司 抗tfr1抗体及其应用
CN120958020A (zh) 2023-03-24 2025-11-14 戴纳立制药公司 Aβ靶向蛋白和使用方法
EP4477236A1 (en) 2023-06-14 2024-12-18 Inatherys Combination therapy for treating a tumor using adc comprising anti-cd71 antibodies and bh3 mimetics
TW202517685A (zh) * 2023-10-26 2025-05-01 美商百健Ｍａ公司 抗運鐵蛋白受體抗體及其用途
WO2025140522A1 (en) * 2023-12-29 2025-07-03 Nona Biosciences (Suzhou) Co., Ltd. Anti-tfr1 antibodies, preparation methods and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005111082A1 (en) * 2004-04-30 2005-11-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-tfr antibody.
WO2014020140A1 (en) * 2012-08-02 2014-02-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of transferrin receptor antagonist for the treatment of thalassemia

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4434156A (en) 1981-10-26 1984-02-28 The Salk Institute For Biological Studies Monoclonal antibodies specific for the human transferrin receptor glycoprotein
BR0008758A (pt) * 1999-01-15 2001-12-04 Genentech Inc Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante
CA2802205C (en) 2002-07-31 2016-01-19 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
WO2005011082A2 (en) 2003-07-23 2005-02-03 Univeral Infusion Technology Drive motor transmission system
US7572895B2 (en) * 2004-06-07 2009-08-11 Raven Biotechnologies, Inc. Transferrin receptor antibodies
CN109485727A (zh) * 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
FR2953841B1 (fr) 2009-12-16 2011-12-30 Centre Nat Rech Scient Anticorps diriges contre le recepteur de la transferrine et leurs utilisations pour l'immunotherapie des tumeurs qui dependent du fer
CA2893794C (en) * 2012-11-08 2021-11-09 University Of Miyazaki Antibody capable of specifically recognizing transferrin receptor
EP3552631A1 (en) * 2018-04-10 2019-10-16 Inatherys Antibody-drug conjugates and their uses for the treatment of cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005111082A1 (en) * 2004-04-30 2005-11-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-tfr antibody.
WO2014020140A1 (en) * 2012-08-02 2014-02-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of transferrin receptor antagonist for the treatment of thalassemia

Also Published As

Publication number Publication date
AU2016296321B2 (en) 2022-09-08
CY1123941T1 (el) 2022-05-27
CA2992509A1 (en) 2017-01-26
JP6858185B2 (ja) 2021-04-14
HK1256088A1 (en) 2019-09-13
CA2992509C (en) 2025-02-04
KR20180028519A (ko) 2018-03-16
RU2018106364A3 (OSRAM) 2019-08-22
PL3325509T3 (pl) 2021-07-19
US11230605B2 (en) 2022-01-25
CN107849136A (zh) 2018-03-27
RU2018106364A (ru) 2019-08-22
IL257065A (en) 2018-03-29
SI3325509T1 (sl) 2021-07-30
AU2016296321A1 (en) 2018-01-25
KR102690998B1 (ko) 2024-07-31
JP2018521691A (ja) 2018-08-09
US20220119543A1 (en) 2022-04-21
EP3325509B1 (en) 2020-12-16
SMT202100134T1 (it) 2021-05-07
WO2017013230A1 (en) 2017-01-26
EP3325509A1 (en) 2018-05-30
RS61586B1 (sr) 2021-04-29
HUE053296T2 (hu) 2021-06-28
US12037408B2 (en) 2024-07-16
RU2737637C2 (ru) 2020-12-01
PT3325509T (pt) 2021-03-12
DK3325509T3 (da) 2021-03-08
CN107849136B (zh) 2022-04-01
HRP20210393T1 (hr) 2021-04-30
BR112018000650A2 (en) 2018-09-18
LT3325509T (lt) 2021-06-10
ES2860988T3 (es) 2021-10-05
US20190092870A1 (en) 2019-03-28
MX2018000569A (es) 2018-09-27

Similar Documents

Publication Publication Date Title
US12037408B2 (en) Method of treating a tumor using anti-TfR antibodies
AU2020286284B2 (en) Novel anti-CD39 antibodies
KR102094022B1 (ko) 항-cd38 항체 및 감쇠 인터페론 알파-2ｂ와의 융합체
KR102847971B1 (ko) 항체-약물 컨쥬게이트 및 이의 암 치료 용도
CN102439040B (zh) 抗TNF‑α抗体和其用途
CN109476742B (zh) Tl1a抗体及其用途
JP2018513149A (ja) Ｃｄ３８に結合する抗体治療剤
CA2934965A1 (en) Novel anti-baff antibodies
JP7419238B2 (ja) Ｐｄ１結合剤
AU2014233503A1 (en) Anti-CD25 antibodies and their uses
WO2021258337A1 (en) Human monoclonal antibodies against tigit for immune related diseases
HK1256088B (en) Anti-tfr antibodies and their use in treating proliferative and inflammatory disorders
BR112018000650B1 (pt) Anticorpos anti-trf e sua utilização no tratamento de transtornos proliferativos e inflamatórios
WO2024251154A1 (zh) 抗gprc5d/bcma/cd3三特异性抗体的制备及其用途
WO2024079482A1 (en) Vegf antibodies
CN117295762A (zh) 抗cd122抗体及其用途
AU2013203712A1 (en) Binding Proteins, Including Antibodies, Antibody Derivatives And Antibody Fragments, That Specifically Bind CD154 And Uses Thereof